| [1] |
Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease-current status and future directions. J Dig Dis, 2015, 16:541-557.
|
| [2] |
Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis, 2015, 35:221-235.
|
| [3] |
Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis, 2015, 239:192-202.
|
| [4] |
Ul Hussain M. Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action. Cell Tissue Res, 2012, 349:405-413.
|
| [5] |
Li G, Cai G, Li D, et al. MicroRNAs and liver disease: viral hepatitis, liver fibrosis and hepatocellular carcinoma. Postgrad Med J, 2014, 90:106-112.
|
| [6] |
Soronen J, Yki-Jarvinen H, Zhou Y, et al. Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep, 2016, 4.
|
| [7] |
Xu Q, Li Y, Shang YF, et al. miRNA-103: molecular link between insulin resistance and nonalcoholic fatty liver disease. World J Gastroenterol, 2015, 21:511-516.
|
| [8] |
Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut, 2015.
|
| [9] |
Leti F, Malenica I, Doshi M, et al. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. Transl Res, 2015, 166:304-314.
|
| [10] |
Feng YY, Xu XQ, Ji CB, et al. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem, 2014, 34:1983-1997.
|
| [11] |
Zhang D, Wang Y, Ji Z, et al. Identification and differential expression of microRNAs associated with fat deposition in the liver of Wistar rats with nonalcoholic fatty liver disease. Gene, 2016, 585:1-8.
|
| [12] |
Xiao J, Bei Y, Liu J, et al. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. J Cell Mol Med, 2016, 20:204-216.
|
| [13] |
Ding J, Li M, Wan X, et al. Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci Rep, 2015, 5:13729.
|
| [14] |
Tessitore A, Cicciarelli G, Del Vecchio F, et al. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer, 2016, 16:3.
|
| [15] |
Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol, 2014, 20:475-485.
|
| [16] |
Yamada H, Ohashi K, Suzuki K, et al. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin Chim Acta, 2015, 446:267-271.
|
| [17] |
Miyaaki H, Ichikawa T, Kamo Y, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int, 2014, 34:e302-307.
|
| [18] |
Salvoza NC, Klinzing DC, Gopez-Cervantes J, et al. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease. PLoS One, 2016, 11:e0153497.
|
| [19] |
Pirola CJ, Fernandez Gianotti T, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut, 2015, 64:800-812.
|
| [20] |
Tan Y, Ge G, Pan T, et al. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One, 2014, 9:e105192.
|
| [21] |
Celikbilek M, Baskol M, Taheri S, et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol, 2014, 6:613-620.
|
| [22] |
Becker PP, Rau M, Schmitt J, et al. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One, 2015, 10:e0142661.
|
| [23] |
Kurtz CL, Fannin EE, Toth CL, et al. Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver. Sci Rep, 2015, 5:12911.
|
| [24] |
Mattis AN, Song G, Hitchner K, et al. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology, 2015, 61:141-152.
|
| [25] |
Ng R, Wu H, Xiao H, et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology, 2014, 60:554-564.
|
| [26] |
Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med, 2015, 35:847-853.
|
| [27] |
Du J, Niu X, Wang Y, et al. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci Rep, 2015, 5:16163.
|
| [28] |
Jiang W, Liu J, Dai Y, et al. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J Gastroenterol Hepatol, 2015, 30:933-943.
|
| [29] |
Hur W, Lee JH, Kim SW, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int J Biochem Cell Biol, 2015, 64:265-276.
|
| [30] |
Zhang ZC, Liu Y, Xiao LL, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol, 2015, 63:1466-1475.
|
